Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease

MT Newswires Live06-10

Akebia Therapeutics (AKBA) said Wednesday that it has secured a new patent covering a once daily dosing regimen for treating anemia secondary to or associated with chronic kidney disease.

The company said that the patent, valid until June 2034, is listed in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.

Akebia said it also received notification of eligibility to extend the expiration of a composition of matter patent covering Vafseo, indicated for treating anemia due to chronic kidney disease in adults receiving dialysis for at least three months. The extension is for five years, it said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642742623?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642742623","market":"hk","top_or_hot":-1,"title":"Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease","media":"MT Newswires Live","content":"<html><body><p> Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA) said Wednesday that it has secured a new patent covering a once daily dosing regimen for treating anemia secondary to or associated with chronic kidney disease.</p><p>The company said that the patent, valid until June 2034, is listed in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book.</p><p>Akebia said it also received notification of eligibility to extend the expiration of a composition of matter patent covering Vafseo, indicated for treating anemia due to chronic kidney disease in adults receiving dialysis for at least three months. The extension is for five years, it said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-10 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA) said Wednesday that it has secured a new patent covering a once daily dosing regimen for treating anemia secondary to or associated with chronic kidney disease.</p><p>The company said that the patent, valid until June 2034, is listed in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book.</p><p>Akebia said it also received notification of eligibility to extend the expiration of a composition of matter patent covering Vafseo, indicated for treating anemia due to chronic kidney disease in adults receiving dialysis for at least three months. The extension is for five years, it said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642742623","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642742623","pubTimestamp":1781096101,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Akebia Therapeutics  said Wednesday that it has secured a new patent covering a once daily dosing regimen for treating anemia secondary to or associated with chronic kidney disease.The company said that the patent, valid until June 2034, is listed in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.Akebia said it also received notification of eligibility to extend the expiration of a composition of matter patent covering Vafseo, indicated for treating anemia due to chronic kidney disease in adults receiving dialysis for at least three months. The extension is for five years, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Akebia Therapeutics获得涵盖慢性肾脏疾病给药方案的新专利","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1.5},"content_text":"Akebia Therapeutics (AKBA) said Wednesday that it has secured a new patent covering a once daily dosing regimen for treating anemia secondary to or associated with chronic kidney disease.The company said that the patent, valid until June 2034, is listed in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.Akebia said it also received notification of eligibility to extend the expiration of a composition of matter patent covering Vafseo, indicated for treating anemia due to chronic kidney disease in adults receiving dialysis for at least three months. The extension is for five years, it said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642742623","isCrawlerRequest":true}